{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T07:30:51Z","timestamp":1765438251914},"reference-count":119,"publisher":"The Journal of Rheumatology","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Current clinical trial designs for pharmacologic interventions in rheumatoid arthritis (RA) do not reflect the innovations in RA diagnosis, treatment, and care in countries where new drugs are most often used. The objective of this project was to recommend revised entry criteria and other study design features for RA clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Recommendations were developed using a modified nominal group consensus method. Canadian Rheumatology Research Consortium (CRRC) members were polled to rank the greatest challenges to clinical trial recruitment in their practices. Initial recommendations were developed by an expert panel of rheumatology trialists and other experts. A scoping study methodology was then used to examine the evidence available to support or refute each initial recommendation. The potential influence of CRRC recommendations on primary outcomes in future trials was examined. Recommendations were finalized using a consensus process.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Recommendations for clinical trial inclusion criteria addressed measures of disease activity [Disease Activity Score 28 using erythrocyte sedimentation rate (DAS28-ESR) &gt; 3.2 PLUS \u2265 3 tender joints using 28-joint count (TJC28) PLUS \u2265 3 swollen joint (SJC28) OR C-reactive protein (CRP) or ESR &gt; upper limit of normal PLUS \u2265 3 TJC28 PLUS \u2265 3 SJC28], functional classification, disease classification and duration, and concomitant RA treatments. Additional recommendations regarding study design addressed rescue strategies and longterm extension.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>There is an urgent need to modify clinical trial inclusion criteria and other study design features to better reflect the current characteristics of people living with RA in the countries where the new drugs will be used.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.110188","type":"journal-article","created":{"date-parts":[[2011,7,16]],"date-time":"2011-07-16T06:34:30Z","timestamp":1310798070000},"page":"2095-2104","source":"Crossref","is-referenced-by-count":12,"title":["Canadian Recommendations for Clinical Trials of Pharmacologic Interventions in Rheumatoid Arthritis: Inclusion Criteria and Study Design: Table 1."],"prefix":"10.3899","volume":"38","author":[{"given":"JACOB","family":"KARSH","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EDWARD C.","family":"KEYSTONE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BOULOS","family":"HARAOUI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. CARTER","family":"THORNE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JANET E.","family":"POPE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VIVIAN P.","family":"BYKERK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WALTER P.","family":"MAKSYMOWYCH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MICHEL","family":"ZUMMER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WILLIAM G.","family":"BENSEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MAJED M.","family":"KRAISHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2011,7,15]]},"reference":[{"key":"2018112909270267000_38.10.2095.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb0803929"},{"key":"2018112909270267000_38.10.2095.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2441"},{"key":"2018112909270267000_38.10.2095.3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/nrd2441-c1","article-title":"Globalization of sponsored clinical trials","volume":"7","author":"Karlberg","year":"2008","journal-title":"Nat Rev Drug Disc"},{"key":"2018112909270267000_38.10.2095.4","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0b013e32832af21b"},{"key":"2018112909270267000_38.10.2095.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.04.028"},{"key":"2018112909270267000_38.10.2095.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.099010"},{"key":"2018112909270267000_38.10.2095.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.116319"},{"issue":"Suppl","key":"2018112909270267000_38.10.2095.8","first-page":"414","article-title":"Serious infections with ocrelizumab in rheumatoid arthritis: Pooled results from double-blind periods of the ocrelizumab Phase III RA Program [abstract]","volume":"62","author":"Emery","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2018112909270267000_38.10.2095.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2008.04.003"},{"key":"2018112909270267000_38.10.2095.10","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0240-3"},{"key":"2018112909270267000_38.10.2095.11","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0553-x"},{"key":"2018112909270267000_38.10.2095.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2008.07.003"},{"key":"2018112909270267000_38.10.2095.13","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181a90cd8"},{"key":"2018112909270267000_38.10.2095.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.109983"},{"key":"2018112909270267000_38.10.2095.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1005843"},{"key":"2018112909270267000_38.10.2095.16","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for good clinical practice E6 (R1). ICH harmonised tripartite guideline, 1996. ICH, Geneva, Switzerland."},{"key":"2018112909270267000_38.10.2095.17","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.74.9.979"},{"key":"2018112909270267000_38.10.2095.18","doi-asserted-by":"publisher","DOI":"10.1080\/1364557032000119616"},{"key":"2018112909270267000_38.10.2095.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"2018112909270267000_38.10.2095.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390105"},{"key":"2018112909270267000_38.10.2095.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"2018112909270267000_38.10.2095.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138461"},{"key":"2018112909270267000_38.10.2095.23","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20078"},{"key":"2018112909270267000_38.10.2095.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"2018112909270267000_38.10.2095.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61000-4"},{"key":"2018112909270267000_38.10.2095.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60944-2"},{"key":"2018112909270267000_38.10.2095.27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.117234"},{"key":"2018112909270267000_38.10.2095.28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh565"},{"key":"2018112909270267000_38.10.2095.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.10.007"},{"key":"2018112909270267000_38.10.2095.30","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081255"},{"key":"2018112909270267000_38.10.2095.31","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090386"},{"key":"2018112909270267000_38.10.2095.32","first-page":"1817","article-title":"The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the illness","volume":"28","author":"Wolfe","year":"2001","journal-title":"J Rheumatol"},{"key":"2018112909270267000_38.10.2095.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000500"},{"key":"2018112909270267000_38.10.2095.34","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080059"},{"key":"2018112909270267000_38.10.2095.35","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq117"},{"key":"2018112909270267000_38.10.2095.36","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101121"},{"key":"2018112909270267000_38.10.2095.37","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.119016"},{"key":"2018112909270267000_38.10.2095.38","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-12-200606200-00003"},{"key":"2018112909270267000_38.10.2095.39","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.080002"},{"key":"2018112909270267000_38.10.2095.40","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq287"},{"key":"2018112909270267000_38.10.2095.41","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2147\/DDDT.S14099","article-title":"Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy","volume":"4","author":"Patel","year":"2010","journal-title":"Drug Des Devel Ther"},{"key":"2018112909270267000_38.10.2095.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60453-5"},{"key":"2018112909270267000_38.10.2095.43","doi-asserted-by":"publisher","DOI":"10.1002\/art.23940"},{"issue":"Suppl","key":"2018112909270267000_38.10.2095.44","first-page":"637","article-title":"LITHE: Tocilizumab inhibits radiographic progression and improves physical function in rheumatoid arthritis (RA) patients (pts) at 2 yrs with increasing clinical efficacy over time [abstract]","volume":"60","author":"Fleischmann","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2018112909270267000_38.10.2095.45","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-008-0125-1"},{"key":"2018112909270267000_38.10.2095.46","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.105197"},{"key":"2018112909270267000_38.10.2095.47","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092932"},{"key":"2018112909270267000_38.10.2095.48","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.044131"},{"key":"2018112909270267000_38.10.2095.49","unstructured":"Akhavan P Bykerk V Sun Y Boire G Pope J Haraoui B \u201cLiberal\u201d (easier to achieve) compared to \u201cstandard\u201d entry criteria improves trial recruitment in a real world practice. Results from the Canadian Early Rheumatoid Arthritis Cohort (CATCH) [abstract]. London: EULAR Scientific Programme. EULAR 2011: SAT0390."},{"key":"2018112909270267000_38.10.2095.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.02.018"},{"key":"2018112909270267000_38.10.2095.51","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/art.1780380106","article-title":"Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity","volume":"38","author":"Smolen","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2018112909270267000_38.10.2095.52","doi-asserted-by":"publisher","DOI":"10.1002\/art.24643"},{"key":"2018112909270267000_38.10.2095.53","doi-asserted-by":"publisher","DOI":"10.1002\/art.24638"},{"key":"2018112909270267000_38.10.2095.54","doi-asserted-by":"publisher","DOI":"10.1002\/art.27348"},{"key":"2018112909270267000_38.10.2095.55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60506-7"},{"key":"2018112909270267000_38.10.2095.56","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092460"},{"key":"2018112909270267000_38.10.2095.57","unstructured":"U.S. Department of Health and Human Services. Clinical development programs for drugs, devices and biological products for the treatment of rheumatoid arthritis (RA). Washington, DC: Food and Drug Administration Center for Drug Evaluation and Research; Arthritis Advisory Committee; Guidance for Industry; volume II. February 1997."},{"key":"2018112909270267000_38.10.2095.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2010.02.007"},{"key":"2018112909270267000_38.10.2095.59","first-page":"216","article-title":"Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis","volume":"66","author":"Pincus","year":"2008","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"2018112909270267000_38.10.2095.60","first-page":"231","article-title":"A randomized controlled trial to evaluate the efficacy of community based physical therapy in the treatment of people with rheumatoid arthritis","volume":"25","author":"Bell","year":"1998","journal-title":"J Rheumatol"},{"key":"2018112909270267000_38.10.2095.61","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350502"},{"key":"2018112909270267000_38.10.2095.62","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1949.02900430001001"},{"key":"2018112909270267000_38.10.2095.63","doi-asserted-by":"publisher","DOI":"10.1002\/art.24266"},{"key":"2018112909270267000_38.10.2095.64","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1524-1"},{"key":"2018112909270267000_38.10.2095.65","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-009-1150-4"},{"key":"2018112909270267000_38.10.2095.66","doi-asserted-by":"publisher","DOI":"10.1002\/art.23721"},{"key":"2018112909270267000_38.10.2095.67","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.119933"},{"key":"2018112909270267000_38.10.2095.68","doi-asserted-by":"publisher","DOI":"10.1002\/art.23964"},{"key":"2018112909270267000_38.10.2095.69","doi-asserted-by":"publisher","DOI":"10.1002\/art.27524"},{"key":"2018112909270267000_38.10.2095.70","doi-asserted-by":"publisher","DOI":"10.1002\/art.24485"},{"key":"2018112909270267000_38.10.2095.71","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.099291"},{"key":"2018112909270267000_38.10.2095.72","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101659"},{"key":"2018112909270267000_38.10.2095.73","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0948"},{"key":"2018112909270267000_38.10.2095.74","doi-asserted-by":"publisher","DOI":"10.1186\/ar2555"},{"key":"2018112909270267000_38.10.2095.75","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092668"},{"key":"2018112909270267000_38.10.2095.76","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094474"},{"key":"2018112909270267000_38.10.2095.77","unstructured":"National Institute for Health and Clinical Excellence (NICE). Rheumatoid arthritis: The management of rheumatoid arthritis in adults. London: National Collaborating Centre for Chronic Conditions; NICE clinical guideline 79. February 2009."},{"key":"2018112909270267000_38.10.2095.78","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken450a"},{"key":"2018112909270267000_38.10.2095.79","doi-asserted-by":"crossref","unstructured":"Bykerk V Akhavan P Hazlewood GS Schieir O Dooley A Haraoui B Canadian recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease modifying anti-rheumatic drugs. J Rheumatol 2011 [in press].","DOI":"10.3899\/jrheum.110207"},{"key":"2018112909270267000_38.10.2095.80","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126532"},{"key":"2018112909270267000_38.10.2095.81","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh088"},{"key":"2018112909270267000_38.10.2095.82","first-page":"2578","article-title":"Regional differences between patients with rheumatoid arthritis (RA) in Canada at initiation of adalimumab treatment in Canada: Results of the Optimization of Humira Trial [abstract]","volume":"36","author":"Haraoui","year":"2009","journal-title":"J Rheumatol"},{"key":"2018112909270267000_38.10.2095.83","first-page":"CD008495","article-title":"Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis","volume":"4","author":"Katchamart","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2018112909270267000_38.10.2095.84","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep331"},{"key":"2018112909270267000_38.10.2095.85","unstructured":"The European Agency for the Evaluation of Medicinal Products . Post-authorisation evaluation of medicines for human use. EMEA public statement on leflunomide (Arava) \u2014 severe and serious hepatic reactions. Document reference EMEA\/H\/5611\/01\/en. London: EMEA; 12 March 2001."},{"key":"2018112909270267000_38.10.2095.86","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.127332"},{"key":"2018112909270267000_38.10.2095.87","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006356"},{"key":"2018112909270267000_38.10.2095.88","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.179"},{"key":"2018112909270267000_38.10.2095.89","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken230"},{"key":"2018112909270267000_38.10.2095.90","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-2456(97)00118-9"},{"key":"2018112909270267000_38.10.2095.91","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61432-X"},{"key":"2018112909270267000_38.10.2095.92","doi-asserted-by":"publisher","DOI":"10.1002\/art.20982"},{"key":"2018112909270267000_38.10.2095.93","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.115832"},{"key":"2018112909270267000_38.10.2095.94","unstructured":"Canadian Agency for Drugs and Technology in Health (CADTH), Therapeutic Review Panel . Biological response modifier agents for adults with rheumatoid arthritis. Ottawa: CADTH; July 2010. [Internet. Accessed June 9, 2011.] Available from: http:\/\/www.cadth.ca\/en\/search?q=biological+response"},{"key":"2018112909270267000_38.10.2095.95","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2003.09.011"},{"key":"2018112909270267000_38.10.2095.96","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Guidance for Industry: Clinical development programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis. Rockville, MD: FDA; 1999."},{"key":"2018112909270267000_38.10.2095.97","unstructured":"The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. Evaluation of medicines for human use: points to consider on clinical investigation of medicinal products other than NSAIDS for treatment of rheumatoid arthritis. CPMP\/EWP\/556\/95 rev 1\/Final. London; 2003."},{"key":"2018112909270267000_38.10.2095.98","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.10.005"},{"key":"2018112909270267000_38.10.2095.99","doi-asserted-by":"crossref","unstructured":"Keystone EC . Clinical implications of understanding radiographic findings in relation to clinical outcomes in rheumatoid arthritis. J Rheumatol Suppl. 2009 June;82:11\u20136.","DOI":"10.3899\/jrheum.090125"},{"key":"2018112909270267000_38.10.2095.100","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.118307"},{"key":"2018112909270267000_38.10.2095.101","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1135-x"},{"key":"2018112909270267000_38.10.2095.102","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730020-00001"},{"key":"2018112909270267000_38.10.2095.103","first-page":"MR000013","article-title":"Strategies to improve recruitment to randomised controlled trials","volume":"4","author":"Treweek","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2018112909270267000_38.10.2095.104","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2753.2007.00821.x"},{"key":"2018112909270267000_38.10.2095.105","first-page":"425","article-title":"The challenge of assuring continued post-trial access to beneficial treatment","volume":"5","author":"Grady","year":"2005","journal-title":"Yale J Health Policy Law Ethics"},{"key":"2018112909270267000_38.10.2095.106","doi-asserted-by":"publisher","DOI":"10.1136\/jme.2008.024711"},{"key":"2018112909270267000_38.10.2095.107","doi-asserted-by":"publisher","DOI":"10.1002\/art.11141"},{"key":"2018112909270267000_38.10.2095.108","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.110007"},{"key":"2018112909270267000_38.10.2095.109","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)01373-7"},{"key":"2018112909270267000_38.10.2095.110","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030817"},{"key":"2018112909270267000_38.10.2095.111","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.028415"},{"key":"2018112909270267000_38.10.2095.112","doi-asserted-by":"crossref","unstructured":"Rahman MU Buchanan J Doyle MK Hsia E Gathany T Parasuraman S Historical trends of patient characteristics in anti-TNF clinical trials for rheumatoid arthritis: an analysis of the literature over the past 16 years [abstract]. Rome: EULAR Scientific Programme. EULAR 2010: SAT0131.","DOI":"10.1136\/ard.2010.146043"},{"key":"2018112909270267000_38.10.2095.113","doi-asserted-by":"publisher","DOI":"10.1002\/art.10817"},{"issue":"Suppl","key":"2018112909270267000_38.10.2095.114","first-page":"S161","article-title":"Early rheumatoid arthritis (ERA) trials have almost no generalizability to ERA patients: Results from a large multi-center cohort [abstract]","volume":"58","author":"Bykerk","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2018112909270267000_38.10.2095.115","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1002\/art.11336","article-title":"Eligibility of rheumatoid arthritis patients seen in clinical practice for rheumatoid arthritis clinical trials: comment on the article by Sokka and Pincus","volume":"48","author":"Yazici","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2018112909270267000_38.10.2095.116","doi-asserted-by":"publisher","DOI":"10.1002\/art.22193"},{"key":"2018112909270267000_38.10.2095.117","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.072447"},{"key":"2018112909270267000_38.10.2095.118","first-page":"1138","article-title":"Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission","volume":"30","author":"Sokka","year":"2003","journal-title":"J Rheumatol"},{"key":"2018112909270267000_38.10.2095.119","first-page":"681","article-title":"Inclusion criteria as widely used for rheumatoid arthritis clinical trials: patient eligibility in a Turkish cohort","volume":"23","author":"Gogus","year":"2005","journal-title":"Clin Exp Rheumatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.110188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T01:05:02Z","timestamp":1560387902000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.110188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,15]]},"references-count":119,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2011,10,1]]},"published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.3899\/jrheum.110188"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.110188","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,15]]}}}